Jean‐Marie Tigaud

951 total citations
20 papers, 736 citations indexed

About

Jean‐Marie Tigaud is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean‐Marie Tigaud has authored 20 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Hepatology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean‐Marie Tigaud's work include Colorectal Cancer Treatments and Studies (9 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Cancer Treatment and Pharmacology (8 papers). Jean‐Marie Tigaud is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Cancer Treatment and Pharmacology (8 papers). Jean‐Marie Tigaud collaborates with scholars based in France, Belgium and Lebanon. Jean‐Marie Tigaud's co-authors include Esteban Cvitkovic, Michel Ducreux, Philippe Rougier, Thierry André, Aimery de Gramont, Christophe Louvet, Jean‐Yves Douillard, Damien Levoir, E. Gamelin and R. Brunet and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Jean‐Marie Tigaud

20 papers receiving 718 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean‐Marie Tigaud France	13	477	387	191	110	100	20	736
Fabiola Lorena Rojas Llimpe Italy	10	500 1.0×	498 1.3×	217 1.1×	57 0.5×	135 1.4×	32	791
Mutsumi Fukunaga Japan	12	343 0.7×	188 0.5×	120 0.6×	58 0.5×	35 0.3×	77	535
Takeo Kosaka Japan	15	219 0.5×	420 1.1×	322 1.7×	36 0.3×	208 2.1×	85	769
Yoshinori Hirashima Japan	13	335 0.7×	238 0.6×	93 0.5×	62 0.6×	98 1.0×	29	572
Shigeru Yamagishi Japan	12	373 0.8×	153 0.4×	243 1.3×	39 0.4×	34 0.3×	45	576
Fritz Lang Austria	12	534 1.1×	240 0.6×	187 1.0×	88 0.8×	12 0.1×	16	640
Beate Haugk United Kingdom	15	326 0.7×	139 0.4×	211 1.1×	72 0.7×	24 0.2×	40	590
Tsukasa Kotoh Japan	14	207 0.4×	472 1.2×	402 2.1×	45 0.4×	105 1.1×	24	758
M Starnawski Austria	3	466 1.0×	660 1.7×	271 1.4×	21 0.2×	268 2.7×	5	862
Hong Jo Choi South Korea	12	276 0.6×	174 0.4×	177 0.9×	26 0.2×	52 0.5×	25	546

Countries citing papers authored by Jean‐Marie Tigaud

Since Specialization

Citations

This map shows the geographic impact of Jean‐Marie Tigaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Marie Tigaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Marie Tigaud more than expected).

Fields of papers citing papers by Jean‐Marie Tigaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Marie Tigaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Marie Tigaud. The network helps show where Jean‐Marie Tigaud may publish in the future.

Co-authorship network of co-authors of Jean‐Marie Tigaud

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Marie Tigaud. A scholar is included among the top collaborators of Jean‐Marie Tigaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Marie Tigaud. Jean‐Marie Tigaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Psimaras, Dimitri, C. Tafani, M. Sallansonnet-Froment, et al.. (2016). Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy. Journal of Neuro-Oncology. 127(2). 373–380. 23 indexed citations

Arrondeau, Jennifer, Olivier Huillard, Camille Tlemsani, et al.. (2015). Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. Expert Opinion on Investigational Drugs. 24(5). 673–687. 7 indexed citations

Beinse, Guillaume, George Emile, Anatole Cessot, et al.. (2015). 2747 A real life experience of bevacizumab in elderly women with advanced ovarian carcinoma. European Journal of Cancer. 51. S545–S546. 1 indexed citations

Emile, George, L. Chauvenet, Jean‐Marie Tigaud, et al.. (2013). A clinical experience of single agent bevacizumab in relapsing ovarian cancer. Gynecologic Oncology. 129(3). 459–462. 17 indexed citations

Ducreux, Michel, Jean‐Luc Raoul, Yacine Merrouche, et al.. (2008). High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases?. Oncology. 74(1-2). 17–24. 15 indexed citations

Mitry, Emmanuel, Michel Ducreux, Mahmoud Ould-Kaci, et al.. (2006). Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Gastroentérologie Clinique et Biologique. 30(3). 357–363. 33 indexed citations

Bouché, Olivier, Marc Ychou, Pascal Burtin, et al.. (2005). Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Annals of Oncology. 16(9). 1488–1497. 107 indexed citations

Ducreux, Michel, Emmanuel Mitry, Mahmoud Ould-Kaci, et al.. (2004). Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Annals of Oncology. 15(3). 467–473. 73 indexed citations

Ducreux, Michel, Emmanuel Mitry, Mahmoud Ould-Kaci, et al.. (2004). Response to the letter “Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patients”, by C. Allior (Ann. Oncol 2004; 15: 1576–1577). Annals of Oncology. 15(10). 1577–1578. 1 indexed citations

10.

Boige, Valérie, Julien Taı̈eb, Mohamed Hebbar, et al.. (2004). Final results of a multicenter phase II study of irinotecan (CPT-11) in patients (pts) with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 22(14_suppl). 4180–4180. 2 indexed citations

11.

Taı̈eb, Julien, Luminita Bonyhay, Michel Ducreux, et al.. (2003). Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer. 98(12). 2664–2670. 58 indexed citations

12.

Lokiec, François, Gabriel Lopez, Jean‐Marie Tigaud, et al.. (2002). Topotecan preceded by oxaliplatin using a 3 week schedule. European Journal of Cancer. 38(14). 1888–1898. 10 indexed citations

13.

Alexandre, Jérôme, Jean‐Marie Tigaud, Marine Gross‐Goupil, et al.. (2002). Combination of Topotecan and Oxaliplatin in Inoperable Hepatocellular Cancer Patients. American Journal of Clinical Oncology. 25(2). 198–203. 20 indexed citations

14.

Lévi, Francis, Sylvie Giacchetti, Rachid Zidani, et al.. (2002). Chronotherapy of Colorectal Liver Metastases. PubMed. 48(38). 259–265. 15 indexed citations

15.

Louvet, Christophe, Thierry André, Jean‐Marie Tigaud, et al.. (2002). Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients. Journal of Clinical Oncology. 20(23). 4543–4548. 237 indexed citations

16.

Goldwasser, François, Marine Gross‐Goupil, Jean‐Marie Tigaud, et al.. (2000). Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Annals of Oncology. 11(11). 1463–1470. 46 indexed citations

17.

Rougier, P, B Paillot, A. Laplanche, et al.. (1997). 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. final results of a randomised trial in metastatic colorectal cancer. European Journal of Cancer. 33(11). 1789–1793. 37 indexed citations

18.

Mahjoubi, Mondher, et al.. (1994). Phase II Trial of Pirarubicin in the Treatment of Advanced Pancreatic Cancer. Cancer Investigation. 12(4). 403–405. 4 indexed citations

19.

Rougier, P, Mario Ghosn, G. Piot, et al.. (1992). Phase II Trial of 7-Day Continuous 5-Fluorouracil Infusion in the Treatment of Advanced Colorectal Carcinoma. Oncology. 49(1). 35–39. 8 indexed citations

20.

Rougier, P, Michel Ducreux, Jean‐Pierre Pignon, et al.. (1991). Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. European Journal of Cancer and Clinical Oncology. 27(10). 1226–1230. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact